Windtree Therapeutics Shares Are Trading Higher After the Company Announced That the Trial Design of Its SEISMiC Phase 2b Has Been Published by the European Society of Cardiology Heart Failure
windtree therapeutics股價上漲,因該公司宣佈其SEISMiC第20億階段的試驗方案已被歐洲心臟病學會心力衰竭分會發布